Investors Say Biopharma Execs Hid New Migraine Drug Issues
Officers and directors of biopharmaceutical company Axsome Therapeutics Inc. were hit with a derivative shareholder suit in New York federal court over claims that they hid issues about Axsome's latest drug...To view the full article, register now.
Already a subscriber? Click here to view full article